Futures are trading dramatically lower as we start the holiday-shortened trading week, following yesterday’s MLK remembrance day. The futures downdraft this morning is being attributed to President ...

In the wake of spiraling tensions between the United States and Iran over Tehran’s violent crackdown of protests, analysts ...

TheFly reported on January 7 that TD Cowen raised its price target on DHR to $270 from $260, maintaining a Buy rating.

If you're thinking of becoming a financial analyst or an accountant, make sure you understand the differences between these ...

We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are ...

The acquisition will allow the diagnostics giant to enter the rapidly growing market for cancer tests Exact Sciences sells Cologuard, the at-home test for colorectal cancer that allows some patients ...

Exact Sciences (EXAS) will likely need to see over $100 a share in a takeover, according to a William Blair analyst, after an earlier report that Abbott Labs (ABT) is in talks to buy the cancer test ...

Colin is an Associate Editor focused on tech and financial news. He has more than three years of experience editing, proofreading, and fact-checking content on current financial events and politics.

After many years of connecting brilliant minds with the world’s leading science employers, New Scientist Jobs has now closed. We want to express our heartfelt thanks to every employer, recruiter, and ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best large cap value stocks to buy now. On September 22, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ ...